Myriad Genetics

MYRIAD GENETICS INC

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.

Mason,,Ohio,,Usa,-,December,28,,2021:,Myriad,Neuroscience,Sign

Analyst Color

News

Upgrades

Health Care

Analyst Ratings

General

MYGN

VCYT

Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its price target to $12.50.

Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade

HubSpot, Inc.

Markets

Trading Ideas

CROX

HUBS

UNFI

This HubSpot Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

BZ_briefs

Earnings

Guidance

Price Target

Movers

UnitedHealthcare will stop covering Myriad Genetics&#39; GeneSight test in 2025, impacting $45 million in revenue. Myriad reaffirms guidance and names a new CEO.

Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO

Myriad Genetics Inc

Press Releases

Biote Announces CEO Retirement and Succession Plan

Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration

Legal

Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay

Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test

Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025

Myriad Genetics Included in Forbes America's Best Employers 2025 List

Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio

Management

Myriad Genetics Announces Senior Leadership Transition

Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth

Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools

BTMD

HOLX

PODD

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Bicara Therapeutics

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

CareDx

Chimerix

Cogent Biosciences

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Geron

GRAIL

Gyre Therapeutics

Immunome

LENZ Therapeutics

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Nurix Therapeutics

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Arcus Biosciences

Replimune Group

Spyre Therapeutics

Vir Biotechnology

Xencor

Zymeworks

Piper Sandler

B of A Securities

Raymond James

Craig-Hallum

Comments

Myriad Genetics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga